Pfizer Ltd. — Regulatory Filings 2020

Jul 14, 2020

Limited

The Capital, 1802 / 1901, Plot No. C - 70, G Block, Bandra Kurla Complex, Bandra (East), Mumbai 400 051. Tel : +91 22 6693 2000 Fax : +91 22 2654 0274

July 14, 2020

The Corporate Relationship Dept. BSE Limited 1st Floor, P.J.Towers Dalal Street, Fort Mumbai - 400 001 Scrip Code: 500680

The Manager, Listing Dept. The National Stock Exchange of India Ltd. Exchange Plaza, 5th Floor, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E) Mumbai - 400 051 Scrip Symbol: PFIZER

Dear Sirs,

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations')

Pursuant to Regulation 23(9) of the Listing Regulations, please find enclosed, disclosure of related party transactions on a consolidated basis, in the format specified in the accounting standards for the year ended March 31, 2020.

The said disclosure is also available on the website of the Company i.e., www.pfizerindia.com

Please take the above on record.

Thanking you,

Yours truly, For Pfizer Limited

Prajeet Nair Company Secretary

Encl: A/a

CIN: L24231MH1950PLC008311

• contactus.india@pfizer.com
• www.pfizerindia.com

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2020

Currency: ₹ in crore

Related party transactions

I. Names of related parties and description of relationships

A. Parties where control exists:

Ultimate holding company: Pfizer Inc., USA

B. Companies collectively exercising significant influence:

Pfizer East India B.V., Netherlands Wyeth LLC, USA Wyeth Holdings Corporation, USA John Wyeth & Brother Limited, UK Warner - Lambert Company, LLC, USA Parke - Davis & Company, LLC, USA Pharmacia Corporation, USA [Collectively holding 63.92% of the aggregate of equity share capital of the Company]

C. Fellow subsidiaries with whom transactions have taken place during the year

Pfizer Products India Private Limited, India Pfizer Innovative Supply Point International BVBA, Belgium Pfizer Service Company BVBA, Belgium Pfizer Worldwide Services, Ireland Pfizer Asia Manufacturing PTE, Singapore Pfizer Canada Inc

D. Key managerial personnel

Mr. S. Sridhar - Managing Director Mr. Milind Patil - Wholetime Director & Chief Financial Officer

Mr. Vivek Dhariwal - Wholetime Director ( upto 14 February 2020)

Mr. Samir Kazi (w.e.f 14 February 2020) Dr. Anurita Majumdar - Wholetime Director ( upto 8 March 2019)

• Mr. R A Shah Independent Director
• Mr. Pradip Shah Independent Director
• Mr. Uday Khanna Independent Director
• Mr. Sunil Lalbhai Independent Director
• Ms.Meena Ganesh Independent Director

E. Relative of Key managerial personnel

Mr. Akhilesh Iyer ( w.e.f 20 February 2019)

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2020

Currency: ₹ in crore

Related party transactions (Continued)

II. Transactions during the year and balances outstanding as at the year end with the related parties are as follows:

31 March 2020			31 March 2019
No. Nature of transactions	Ultimateholdingcompany	Companiesexercisingsignificantinfluence	Fellowsubsidiaries	Total	Ultimateholdingcompany	Companiesexercisingsignificantinfluence	Fellowsubsidiaries	Total
1 Service income	-	-	55.19	55.19	0.37	-	50.56	50.93
2 Recovery of expenses	0.54	0.03	0.19	0.76	-	-	0.36	0.36
3 Purchase of stock-in-trade	-	-	393.41	393.41	-	-	396.42	396.42
4 Purchase of raw / bulk materials	-	-	115.05	115.05	-	-	49.98	49.98
5 Reimbursement of expenses	-	-	-	-	0.27	-	-	0.27
6 Dividend in respect of the year ended 31 March 2020/2019	-	65.77	-	65.77	-	58.49	-	58.49
7 Liablity written back	-	1.42	8.59	10.01	-	-	-	-
		31 March 2020					31 March 2019
No. Nature of transactions	Ultimateholdingcompany	Companiesexercisingsignificantinfluence	Fellowsubsidiaries	Total	Ultimateholdingcompany	Companiesexercisingsignificantinfluence	Fellowsubsidiaries	Total
8 Outstanding as at the year end – Due from	0.54	0.09	20.99	21.62	0.33	0.06	19.21	19.60
9 Outstanding as at the year end – Due to	11.18	6.47	271.20	288.85	10.52	7.84	254.97	273.33

Key managerial personnel

	No. Nature of transactions	Year ended31 March 2020	Year ended31 March 2019
1	Remuneration to key management personnel *	9.22	10.50

* Excludes amounts payable to key management personnel towards gratuity and compensated absences.

Details of material transactions during the year:

		Year ended	Year ended
		31 March 2020	31 March 2019
a)	Service income
	Pfizer Products India Private Limited	25.60	23.22
	Pfizer Worldwide Services	29.59	27.34
b)	Recovery of expenses
	Pfizer Products India Private Limited	0.19	0.34
	Pfizer Inc., USA	0.54	-
c)	Purchase of stock in trade
	Pfizer Innovative Supply Point Intl BVBA, Belgium	80.21	258.18
	Pfizer Service Company BVBA, Belgium	300.36	131.93
d)	Purchase of raw/ bulk materials
	Pfizer Service Company BVBA, Belgium	111.62	46.87
e)	Reimbursement of expenses
	Pfizer Inc., USA	-	0.27
f)	Dividend paid
	Pfizer East India B.V.	40.92	36.37
	Wyeth LLC, USA	12.64	11.24
g)	Remuneration to key management personnel
	S. Sridhar	4.11	3.55
	Milind Patil	2.10	1.59
	Vivek Dhariwal	1.88	2.53
	Samir Kazi	0.16	-
	Dr. Anurita Majumdar	-	1.96

Pfizer Limited

DISCLOSURE OF RELATED PARTY TRANSACTIONS FOR THE FINANCIAL YEAR ENDED MARCH 31, 2020

Currency: ₹ in crore

Related party transactions (Continued)

		As on31 March 2020	As on31 March 2019
h)	Outstanding as at the year end due fromPfizer Worldwide ServicesPfizer Products India Private Limited, India	5.7015.29	5.4713.74
i)	Outstanding as at the year end due toPfizer Innovative Supply Point Intl BVBA, BelgiumPfizer Service Company BVBA, BelgiumPfizer Export Company, Ireland	15.81152.5582.85	62.4983.9784.70